secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0000950170-24-031138
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa reports Q4 2023 net loss $33.3M; cash into H1 2026; key pipeline milestones on track
--------------------------------------------------------------------------------

- Net loss Q4 2023 $33.3M ($30.8M prior year); FY net loss $135.4M; cash $237M, runway into H1 2026.
- MRT-2359 MYC-driven solid tumors Phase 1/2; recommended Phase 2 dose expected Q2 2024; Fast Track for SCLC and NSCLC.
- MRT-6160 VAV1 MGD IND filing planned Q2 2024; Phase 1 SAD/MAD study start mid-2024.
- MRT-8102 NEK7 program first development candidate nominated; IND submission targeted Q1 2025.
- Entered Roche collaboration; $50M upfront, potential >$2B milestones plus royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017024031138/0000950170-24-031138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017024031138/glue-20240314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-031138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer